Study of INBRX-109 in Conventional Chondrosarcoma

Clinical Trial Title

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

National Clinical Trial Number:

NCT04950075

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Protocol Description:

This is a randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. INBRX-109 is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have conventional chondrosarcoma that is unresectable (=inoperable) or metastatic.
  • Have radiologic progression of disease per RECISTv1.1 criteria within 6 months prior to screening for this study.
  • Have adequate hematologic, coagulation, hepatic and renal function as defined per protocol.
  • Have estimated life expectancy of at least 12 weeks.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Marta Batus, MD

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Location

Rush University Medical Center

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more